Linhai Zhu

878 total citations
55 papers, 605 citations indexed

About

Linhai Zhu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Linhai Zhu has authored 55 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Linhai Zhu's work include Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Linhai Zhu is often cited by papers focused on Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Linhai Zhu collaborates with scholars based in China, Japan and United States. Linhai Zhu's co-authors include Wang Lv, Hongchang Shen, Jian Hu, Hongxin Cao, Tizhong Shan, Yizhen Wang, Yanling Ren, Xiao Qu, Jiajun Du and Yiqing Wang and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Linhai Zhu

45 papers receiving 599 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linhai Zhu China 14 272 183 138 98 95 55 605
Johan Bourghardt Fagman Sweden 11 282 1.0× 158 0.9× 57 0.4× 84 0.9× 165 1.7× 25 716
Yubin Guo China 12 315 1.2× 140 0.8× 45 0.3× 57 0.6× 158 1.7× 20 653
Longjiang Shao United States 16 405 1.5× 86 0.5× 196 1.4× 199 2.0× 43 0.5× 24 834
Naren Gupta United States 11 320 1.2× 145 0.8× 122 0.9× 88 0.9× 109 1.1× 22 606
Elizabeth A. Wellberg United States 19 512 1.9× 344 1.9× 74 0.5× 266 2.7× 62 0.7× 39 979
Е. Л. Лушникова Russia 10 157 0.6× 70 0.4× 55 0.4× 49 0.5× 54 0.6× 140 475
Yanqing Jiang China 10 245 0.9× 105 0.6× 28 0.2× 64 0.7× 64 0.7× 16 454
Kouseki Hirade Japan 14 297 1.1× 85 0.5× 36 0.3× 55 0.6× 46 0.5× 38 548
Haiying Liu China 12 176 0.6× 433 2.4× 137 1.0× 95 1.0× 72 0.8× 26 814

Countries citing papers authored by Linhai Zhu

Since Specialization
Citations

This map shows the geographic impact of Linhai Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linhai Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linhai Zhu more than expected).

Fields of papers citing papers by Linhai Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linhai Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linhai Zhu. The network helps show where Linhai Zhu may publish in the future.

Co-authorship network of co-authors of Linhai Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Linhai Zhu. A scholar is included among the top collaborators of Linhai Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linhai Zhu. Linhai Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Liu, Jia-Cong, Yucheng Ma, Wang Lv, et al.. (2025). Efficacy and safety of anlotinib plus EGFR tyrosine kinase inhibitors in slow- or locally progressing non-small cell lung cancer after adjuvant therapy. Translational Lung Cancer Research. 14(4). 1371–1383.
4.
Yang, Yuhong, Jia-Cong Liu, Linhai Zhu, et al.. (2025). Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations. Translational Lung Cancer Research. 14(2). 538–551.
5.
Liu, Jia-Cong, et al.. (2024). Intercostal approach VATS is feasible for large-sized anterior mediastinal tumors. Scientific Reports. 14(1). 17227–17227. 2 indexed citations
6.
7.
Liu, Jia-Cong, Linhai Zhu, Zhongjie Lu, et al.. (2024). Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?. Journal of Cancer Research and Clinical Oncology. 150(3). 161–161. 3 indexed citations
8.
Mo, Shaocong, et al.. (2024). Prognostic implication of UBE2C + CD8 + T cell in neoadjuvant immune checkpoint blockade plus chemotherapy for locally advanced esophageal cancer. International Immunopharmacology. 130. 111696–111696. 2 indexed citations
9.
Liu, Jia-Cong, Luming Wang, Wang Lv, et al.. (2024). Clinical evaluation of the impact of mediastinal tumour size on the subxiphoid approach video-assisted thoracoscopic surgery. Interdisciplinary CardioVascular and Thoracic Surgery. 38(2).
10.
He, Cheng, Luming Wang, Linhai Zhu, et al.. (2023). The implications of N6-methyladenosine (m6A) modification in esophageal carcinoma. Molecular Biology Reports. 50(10). 8691–8703. 2 indexed citations
11.
12.
13.
14.
Cheng, Hong, et al.. (2022). Value of Contrast-Enhanced Ultrasound in Adjusting the Classification of Chinese-TIRADS 4 Nodules. International Journal of Endocrinology. 2022. 1–6. 7 indexed citations
15.
16.
Feng, Qingling, Haiyan Cao, Yan Yang, et al.. (2021). Somatic Mutation Profiling of Papillary Thyroid Carcinomas by Whole-exome Sequencing and Its Relationship with Clinical Characteristics. International Journal of Medical Sciences. 18(12). 2532–2544. 5 indexed citations
17.
Zhu, Linhai, et al.. (2020). KIF15 contributes to cell proliferation and migration in breast cancer. Human Cell. 33(4). 1218–1228. 24 indexed citations
18.
Chen, Xiaowei, Zhaofei Pang, Yu Wang, et al.. (2020). Cezanne contributes to cancer progression by playing a key role in the deubiquitination of IGF-1R.. American Journal of Cancer Research. 10(12). 4342–4356. 5 indexed citations
19.
Cao, Hongxin, Wei Dong, Xiao Qu, et al.. (2016). Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC. Scientific Reports. 6(1). 31072–31072. 22 indexed citations
20.
Cao, Hongxin, Wei Ma, Linhai Zhu, et al.. (2016). Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis. Clinical Drug Investigation. 37(2). 135–153. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johan Bourghardt Fagman Breakdown of academic impact, for papers by Yubin Guo Breakdown of academic impact, for papers by Longjiang Shao Breakdown of academic impact, for papers by Naren Gupta Breakdown of academic impact, for papers by Elizabeth A. Wellberg Breakdown of academic impact, for papers by Е. Л. Лушникова Breakdown of academic impact, for papers by Yanqing Jiang Breakdown of academic impact, for papers by Kouseki Hirade Breakdown of academic impact, for papers by Haiying Liu
Rankless by CCL
2026